|
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes
|
Jun 2023
|
European Journal of Haematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
|
Jun 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery?
|
Jun 2023
|
Leukemia & Lymphoma
|
aplastic anemia
|
|
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study
|
Jun 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Therapy-related myelodysplastic syndromes in the genomics era
|
Jun 2023
|
Bulletin du Cancer
|
myelodysplastic syndromes (MDS)
|
|
Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia
|
Jun 2023
|
Blood
|
aplastic anemia
|
|
Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction
|
Jun 2023
|
SAGE Open Medicine
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria
|
Jun 2023
|
Blood
|
aplastic anemia
|
|
Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough
|
Jun 2023
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
|
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria
|
Jun 2023
|
Blood Advances
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
